---
title: 'Manufacturing Daily Summary: What Happened on November 4, 2026'
headline: Wacker Biotech adds newer RNA formats to manufacturing services
description: Its offering spans nucleic-acid development, formulation and GMP production.
url: https://thebench.bio/news/manufacturing/2026-11-04
topic: manufacturing
date: '2026-11-04'
covers:
- '2026-11-04'
date_published: '2026-11-04T12:02:46Z'
date_modified: '2026-11-04T12:02:46Z'
tags:
- Manufacturing
sources: 1
publisher: TheBench.Bio
---
# Manufacturing Daily Summary: What Happened on November 4, 2026
**Wacker Biotech adds newer RNA formats to manufacturing services**
Its offering spans nucleic-acid development, formulation and GMP production.
## Today in brief
Wacker Biotech offers an integrated platform for nucleic-acid medicines, from plasmid DNA and RNA through lipid nanoparticle formulation, analytical development and GMP manufacturing. [1] It has supplied clinical material for two RNA vaccine candidates that reached Phase III, and says customers can use one partner instead of coordinating multiple vendors. [1]
## Also worth knowing
- Wacker Biotech has added circular RNA, self-amplifying RNA and siRNA capabilities, and launched Contract Research Services at its Munich research center in 2026. [1]
## The day in numbers
- **750+**: GMP batches produced across vaccine modalities, including two commercial products. [1]
- **120+**: GMP plasmid DNA batches produced at Wacker Biotech's San Diego facility, which has made plasmid DNA for more than two decades. [1]
## Sources
1. [The CDMO partner for next-gen medicine](), European Biotechnology, 2026-11-04
---
TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.
[1]: